FASN and colorectal carcinoma: The good news is that next-generation FASN inhibitors, including TVB-3166 and TVB-2640 (Denifanstat), have shown tremendous antitumor potential in preclinical breast and CRC models, enabling patients to actually benefit from FASN inhibition.333